Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia

References

• Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med., 344, 1031–1037.
   Google Scholar
• Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., et al. (2002) "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias", Blood, 100, 1965–1971.
   Web of Science ®Google Scholar
• Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., et al. (2002) "Hematologic and cytoge-netic responses to imatinib mesylate in chronic myelogenous leukemia", N. EngL J. Med., 346, 645–652.
   PubMed Web of Science ®Google Scholar
• Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., et al. (2002) . "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study", Blood, 99, 1928–1937.
   PubMed Web of Science ®Google Scholar
• Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., et al. (2002) "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study", Blood, 99, 3530 — 3539.
   PubMed Web of Science ®Google Scholar
• Wassmann, B., Pfeifer, H., Scheuring, U., Klein, S.A., Gokbuget, N., Binckebanck, A., et al. (2002) "Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)", Leukemia, 16, 2358 — 2365.
   Google Scholar
• Huettner, C.S., Zhang, P., Van, E.R. and Tenen, D.G. (2000) "Reversibility of acute B-cell leukaemia induced by BCR-ABL1", Nat. Genet., 24, 57–60.
   PubMed Web of Science ®Google Scholar
• Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., et al. (1996) "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nat. Med., 2, 561–566.
   Web of Science ®Google Scholar
• Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. and Kantarjian, H.M. (1999) "The biology of chronic myeloid leukemia", N. Engl. J. Med., 341, 164 — 172.
   Google Scholar
• Gambacorti-Passerini, C., Barth, R., Le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., et al. (2000) "Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL( +) leukemic cells to the abl inhibitor STI571", J. Natl. Cancer Inst., 92, 1641–1650.
   Web of Science ®Google Scholar
• Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L. and Smith, K.D. (2002) "Alpha 1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571", Blood, 99, 713 — 715.
   Google Scholar
• Le Coutre, P., Kreuzer, K.A., Na, I.K., Lupberger, J., Holdoff, M., Appelt, C., et al. (2002) "Determination of alpha-1 acid glycoprotein in patients with Ph + chronic myeloid leukemia during the first 13 weeks of therapy with STI571", Blood Cells MoL Dis., 28, 75–85.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini, C., Le Coutre, P., Zucchetti, M. and D'Incalci, M. (2002) "Binding of imatinib by alpha(1)-acid glycoprotein", Blood, 100, 367— 368.
   Google Scholar
• Petzer, A.L., Gunsilius, E., Hayes, M., Stockhammer, G., Duba, H.C., Schneller, F., et al. (2002) "Low concentrations of STI571 in the cerebrospinal fluid: a case report", Br. J. HaematoL, 117, 623 — 625.
   Web of Science ®Google Scholar
• Le Coutre, P., Tassi, E., Varella-Garcia, M., Barth, R., Mologni, L., Cabrita, G., et al. (2000) "Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplifica-tion", Blood, 95, 1758 — 1766.
   PubMed Web of Science ®Google Scholar
• Weisberg, E. and Griffin, J.D. (2000) "Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-trans-formed hematopoietic cell lines", Blood, 95, 3498— 3505.
   Google Scholar
• Mahon, F.X., Deininger, M.W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M., et al. (2000) "Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance", Blood, 96, 1070 — 1079.
   Google Scholar
• Hochhaus, A., Kreil, S., Corbin, A.S., La Rosee, P., Muller, M.C., Lahaye, T., et al. (2002) "Molecular and chromosomal mechan-isms of resistance to imatinib (STI571) therapy", Leukemia, 16, 2190–2196.
   PubMed Web of Science ®Google Scholar
• Knight, Z.A. (2000) "Another possible mechanism of resistance to STI571", Blood, 96, 4003–4005.
   PubMed Web of Science ®Google Scholar
• Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., et al. (2001) "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification", Science, 293, 876–880.
   PubMed Web of Science ®Google Scholar
• Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B. and Kuriyan, J. (2000) "Structural mechanism for STI-571 inhibition of abelson tyrosine kinase", Science, 289, 1938 — 1942.
   Web of Science ®Google Scholar
• Barthe, C., Cony-Makhoul, P., Melo, IV. and Mahon, J.R. (2001) "Roots of clinical resistance to STI-571 cancer therapy", Science, 293, 2163.
   PubMedGoogle Scholar
• Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., et al. (2001) "Roots of clinical resistance to STI-571 cancer therapy", Science, 293, 2163.
   PubMed Web of Science ®Google Scholar
• von Bubnoff, N., Schneller, F., Peschel, C. and Duyster, J. (2002) "BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a pro-spective study", Lancet, 359, 487–491.
   PubMed Web of Science ®Google Scholar
• Hofmann, W.K., Jones, L.C., Lemp, N.A., de Vos, S., Gschaidme-ier, H., Hoelzer, D., et al. (2002) "Ph( +) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation", Blood, 99, 1860–1862.
   PubMed Web of Science ®Google Scholar
• Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., et al. (2002) "High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resis-tance", Blood, 99, 3472–3475.
   PubMed Web of Science ®Google Scholar
• Shah, N., Nicoll, J., Nagar, B., Gorre, M., Paquette, R., Kuriyan, J., et al. (2002) "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia", Cancer Cell, 2, 117 — 125.
   Google Scholar
• Goddard, J.M., Weiland, ii. and Capecchi, M.R. (1986) "Isolation and characterization of Caenorhabditis elegans DNA sequences homologous to the v-abl oncogene", Proc. Natl. Acad. Sci. USA, 83, 2172–2176.
   PubMed Web of Science ®Google Scholar
• Basler, K. and Hafen, E. (1988) "Control of photoreceptor cell fate by the sevenless protein requires a functional tyrosine kinase domain", Cell, 54, 299 — 311.
   Google Scholar
• Stapleton, D., Mitchelhill, K.I., Gao, G., Widmer, J., Michell, B.J., Teh, T., et al. (1996) "Mammalian AMP-activated protein kinase subfamily", J. Biol. Chem., 271, 611–614.
   Web of Science ®Google Scholar
• Azam, M., Latek, R.R. and Daley, G.Q. (2003) "Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by muta-genesis of BCR-ABL", Cell, 112, 831–843.
   Google Scholar
• Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., et al. (2002) "Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment", Blood, 100, 1014–1018.
   PubMed Web of Science ®Google Scholar
• Hofmann, W.K., Komor, M., Wassmann, B., Jones, L.C., Gschaidmeier, H., Hoelzer, D., et al. (2003) "Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph + acute lymphoblastic leukemia", Blood, 102, 659–661.
   PubMed Web of Science ®Google Scholar
• Hofmann, W.K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H.P., et al. (2002) "Relation between resistance of Philadelphia-chromosome-positive acute lymphoblas-tic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study", Lancet, 359, 481–486.
   PubMed Web of Science ®Google Scholar
• Desiderio, S. (1997) "Role of Btk in B cell development and signaling", Curr. Opin. ImmunoL, 9, 534— 540.
   PubMed Web of Science ®Google Scholar
• Satterthwaite, A.B., Willis, F., Kanchanastit, P., Fruman, D., Cantley, L.C., Helgason, C.D., et al. (2000) "A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase", Proc. Natl. Acad. Sci. USA, 97, 6687–6692.
   PubMed Web of Science ®Google Scholar
• Takata, M. and Kurosaki, T. (1996) "A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospho-lipase C-gamma 2", J. Exp. Med., 184, 31–40.
   PubMed Web of Science ®Google Scholar
• Komatani, H., Kotani, H., Hara, Y., Nakagawa, R., Matsumoto, M., Arakawa, H., et al. (2001) "Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure", Cancer Res., 61, 2827 — 2832.
   Google Scholar
• Wilson, M., DeRisi, J., Kristensen, H.H., Imboden, P., Rane, S., Brown, P.O., et al. (1999) "Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization", Proc. Natl. Acad. Sci. USA, 96, 12833— 12838.
   PubMed Web of Science ®Google Scholar
• DeRisi, J., van den Hazel, B., Marc, P., Balzi, E., Brown, P., Jacq, C., et al. (2000) "Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants", FEBS Lett., 470, 156 — 160.
   Google Scholar
• Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A.G., Bittner, M.L., Meltzer, P.S., et al. (2000) "Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray", Cancer Res., 60, 4161 —4166.
   Google Scholar
• Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, IS., Rosenwald, A., et al. (2000) "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, 503— 511.
   Google Scholar
• West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., et al. (2001) "Predicting the clinical status of human breast cancer by using gene expression profiles", Proc. Natl. Acad. Sci. USA, 98, 11462–11467.
   PubMed Web of Science ®Google Scholar
• Ahr, A., Karn, T., Solbach, C., Seiter, T., Strebhardt, K., Holtrich, U., et al. (2002) "Identification of high risk breast-cancer patients by gene expression profiling", Lancet, 359, 131–132.
   Google Scholar
• Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, RI., et al. (2002) "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma", N. Engl. J. Med., 346, 1937–1947.
   Web of Science ®Google Scholar
• Hofmann, W.K., de Vos, S., Tsukasaki, K., Wachsman, W., Pinkus, G.S., Said, J.W., et al. (2001) "Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray", Blood, 98, 787–794.
   Google Scholar